Trastuzumab deruxtecan (DS-8201a) + Trastuzumab deruxtecan (DS-8201a) + Pembrolizumab
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Non-small Cell Lung Carcinoma
Trial Timeline
Feb 10, 2020 → Mar 31, 2027
NCT ID
NCT04042701About Trastuzumab deruxtecan (DS-8201a) + Trastuzumab deruxtecan (DS-8201a) + Pembrolizumab
Trastuzumab deruxtecan (DS-8201a) + Trastuzumab deruxtecan (DS-8201a) + Pembrolizumab is a phase 1 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04042701. Target conditions include Breast Cancer, Non-small Cell Lung Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042701 | Phase 1 | Active |
Competing Products
20 competing products in Breast Cancer